Summit Therapeutics Inc. Noncurrent Financial Liabilities At Fair Value Through Profit Or Loss Designated Upon Initial Recognition
Summit Therapeutics Inc. (SMMT) had Noncurrent Financial Liabilities At Fair Value Through Profit Or Loss Designated Upon Initial Recognition of GBP 0 as of 2019-12-31, per its 20-F filed 2020-04-30.
Discontinued › Notes
ifrs-full:NoncurrentFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognition · last filed 2020-04-30
- 2019-12-31: Noncurrent Financial Liabilities At Fair Value Through Profit Or Loss Designated Upon Initial Recognition 0.00 GBP.
- 2019-10-31: Noncurrent Financial Liabilities At Fair Value Through Profit Or Loss Designated Upon Initial Recognition 0.00 GBP.
- 2019-07-31: Noncurrent Financial Liabilities At Fair Value Through Profit Or Loss Designated Upon Initial Recognition 0.00 GBP.
- 2019-04-30: Noncurrent Financial Liabilities At Fair Value Through Profit Or Loss Designated Upon Initial Recognition 0.00 GBP.
| Period end | Noncurrent Financial Liabilities At Fair Value Through Profit Or Loss Designated Upon Initial Recognition |
|---|---|
| 2019-12-31 | 0.00 GBP 20-F · filed 2020-04-30 |
| 2019-10-31 | 0.00 GBP 6-K · filed 2019-12-17 |
| 2019-07-31 | 0.00 GBP 6-K · filed 2019-10-11 |
| 2019-04-30 | 0.00 GBP 6-K · filed 2019-06-12 |
| 2019-01-31 | 0.00 GBP 20-F · filed 2020-04-30 |
| 2018-10-31 | 0.00 GBP 6-K · filed 2018-12-11 |
| 2018-07-31 | 0.00 GBP 6-K · filed 2018-09-20 |
| 2018-04-30 | 3.23M GBP 6-K · filed 2018-06-05 |
| 2018-01-31 | 3.09M GBP 20-F · filed 2020-04-30 |
| 2017-01-31 | 5.92M GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |